Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo gets a “Chill”

This article was originally published in The Tan Sheet

Executive Summary

FDA grants the Allegan, Mich.-based firm approval for a generic version of GlaxoSmithKline's Fruit Chill-flavored Nicorette gum (nicotine polacrilex 2 mg) May 24. In 2006 Perrigo received generic approval for Nicorette Fresh Mint smoking cessation gum (1"The Tan Sheet" June 19, 2006, p. 13)...

You may also be interested in...



New Products In Brief

Perrigo generic Nicorette approval: The Allegan, Mich.-based generics manufacturer has received FDA approval to market store-brand versions of GlaxoSmithKline's Nicorette Fresh Mint (coated nicotine polacrilex gum 2 mg and 4 mg) smoking cessation gum, the firm announces June 14. Retail sales for GSK's Fresh Mint gum were approximately $100 mil. for the past 12 months. Perrigo currently produces generic versions of GSK's uncoated NRT gum products as well as nicotine polacrilex lozenges equivalent to GSK's Commit product. "We are pleased with this important addition to our store brand nicotine replacement therapy product offerings, even though some sales may come at the expense of our uncoated gum products," Executive VP and General Manager - Perrigo Consumer Healthcare John Hendrickson states. The product will begin shipping to food, drug, mass market, dollar store and club store retailers in the fourth quarter and will cost approximately 25% to 40% less than the branded, the firm says...

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel